ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES

1 - 49 . (canceled)

50 : A bispecific antibody or bispecific antibody fragment thereof that specifically binds to two different antigens, wherein one of the antigens is IL-13,

wherein the bispecific antibody or bispecific antibody fragment thereof comprises a first pair of polypeptides and a second pair of polypeptides;

wherein the first pair of polypeptides comprise an outer (N-terminal) variable light chain domain linked to an inner (C-terminal) variable light chain domain which is linked to a constant light chain domain (CL), and the second pair of polypeptides comprise an outer (N-terminal) variable heavy chain domain linked to an inner (C-terminal) variable heavy chain domain which is linked to a constant heavy chain domain (CH1); and wherein:

(a) the outer (N-terminal) variable light chain domain comprises the amino acid sequence of SEQ ID NO: 1, and the outer (N-terminal) variable heavy chain domain comprises the amino acid sequence of SEQ ID NO: 2;

(b) the inner (C-terminal) variable light chain domain comprises the amino acid sequence of SEQ ID NO: 1, and the inner (C-terminal) variable heavy chain domain comprises the amino acid sequence of SEQ ID NO: 2;

(c) the outer (N-terminal) variable light chain domain comprises the amino acid sequences of RASESVDSYGQSYMH (SEQ ID NO: 8), LASNLES (SEQ ID NO: 9), and QQNAEDSRT (SEQ ID NO: 10), and the outer (N-terminal) variable heavy chain domain comprises the amino acid sequences GFSLTDSSIN (SEQ ID NO: 11), DGRID (SEQ ID NO: 12), and DGYFPYAMDF (SEQ ID NO: 13), or

(d) the inner (C-terminal) variable light chain domain comprises the amino acid sequences RASESVDSYGQSYMH (SEQ ID NO: 8), LASNLES (SEQ ID NO: 9), and QQNAEDSRT (SEQ ID NO: 10), and the inner (C-terminal) variable heavy chain domain comprises the amino acid sequences GFSLTDSSIN (SEQ ID NO: 11), DGRID (SEQ ID NO: 12), and DGYFPYAMDF (SEQ ID NO: 13).

51 : The bispecific antibody or bispecific antibody fragment thereof of claim 50 that further comprises additional constant region domains.

52 : The bispecific antibody or bispecific antibody fragment thereof of claim 51 , wherein the additional constant region domains consist of C H2 and C H3 .

53 : The bispecific antibody or bispecific antibody fragment thereof of claim 50 that further comprises a label, wherein the label is a radiolabel, fluorophore, chromophore, imaging agent, or metal ion.

54 : The bispecific antibody or bispecific antibody fragment thereof of claim 50 that is further conjugated to an effector molecule.

55 : The bispecific antibody or bispecific antibody fragment thereof of claim 54 , wherein the effector molecule is a heterologous polypeptide, drug, radionucleotide, or toxin.

56 : The bispecific antibody or bispecific antibody fragment thereof of claim 50 , wherein the bispecific antibody or bispecific antibody fragment thereof neutralizes IL-13 activity and preferably neutralizes IL-13 mediated cell proliferation in TF-1 cells.

57 : A nucleic acid molecule encoding the bispecific antibody or bispecific antibody fragment thereof of claim 50 .

58 : A vector comprising the nucleic acid molecule of claim 57 .

59 : A host cell comprising the vector of claim 58 .

60 : A pharmaceutical composition comprising the bispecific antibody or bispecific antibody fragment thereof of claim 50 and a pharmaceutically acceptable carrier.

61 : A method of manufacturing the bispecific antibody or bispecific antibody fragment thereof of claim 50 comprising expressing a nucleic acid molecule encoding the bispecific antibody or bispecific antibody fragment thereof in a suitable host cell.

62 : A kit comprising the bispecific antibody or bispecific antibody fragment thereof of claim 50 and instructions for use.